News
SONN
1.290
-3.01%
-0.040
Sonnet BioTherapeutics Q2 EPS $(0.89) Misses $(0.79) Estimate
Benzinga · 5h ago
Based on the provided financial report articles, I generated the title for the article: "Sonnet BioTherapeutics, Inc. (SONN) Reports Financial Results for the Second Quarter of 2024" Please note that the title may not be exact, as the provided text does not contain a clear title. However, based on the content, I inferred the title to be related to Sonnet BioTherapeutics' financial results for the second quarter of 2024.
Press release · 20h ago
Weekly Report: what happened at SONN last week (0505-0509)?
Weekly Report · 1d ago
Sonnet Biotherapeutics Holdings Inc <SONN.OQ> expected to post a loss of 92 cents a share - Earnings Preview
Reuters · 4d ago
Weekly Report: what happened at SONN last week (0428-0502)?
Weekly Report · 05/05 12:13
Sonnet Chief Medical Officer, Richard Kenney, M.D., to Present at the 6th Annual Cytokine-Based Drug Development Summit
Barchart · 05/01 08:00
Weekly Report: what happened at SONN last week (0421-0425)?
Weekly Report · 04/28 12:26
12 Health Care Stocks Moving In Thursday's Pre-Market Session
Benzinga · 04/24 12:06
Weekly Report: what happened at SONN last week (0414-0418)?
Weekly Report · 04/21 12:25
Sonnet Releases Virtual Investor "What This Means" Segment
Barchart · 04/16 08:10
Weekly Report: what happened at SONN last week (0407-0411)?
Weekly Report · 04/14 12:10
Weekly Report: what happened at SONN last week (0331-0404)?
Weekly Report · 04/07 12:09
Sonnet BioTherapeutics Is Maintained at Buy by Chardan Capital
Dow Jones · 04/07 11:44
Sonnet BioTherapeutics Price Target Maintained With a $20.00/Share by Chardan Capital
Dow Jones · 04/07 11:44
Chardan Capital Maintains Buy on Sonnet BioTherapeutics, Maintains $20 Price Target
Benzinga · 04/07 11:34
Sonnet Biotherapeutics Holdings Inc trading resumes
TipRanks · 04/04 13:45
Sonnet BioTherapeutics Reports Positive Phase 1b/2a Data For SON-1010
NASDAQ · 04/04 13:27
Sonnet BioTherapeutics Holdings Announces Safety Results Of Son-1010 At Highest Dose Combined With Atezolizumab In Phase 1b/2a Clinical Trial In Adult Patients With Advanced Solid Tumors Or Platinum-resistant Ovarian Cancer
Benzinga · 04/04 13:05
Sonnet says SON-1010 demonstrates ‘strong safety profile’ in atezolizumab combo
TipRanks · 04/04 13:05
SONNET BIOTHERAPEUTICS HOLDINGS INC - TOPLINE SAFETY DATA SUGGEST CLINICAL BENEFIT OF SON-1010 WITH ATEZOLIZUMAB
Reuters · 04/04 13:00
More
Webull provides a variety of real-time SONN stock news. You can receive the latest news about Sonnet Biotherapeutc Hldng Inc through multiple platforms. This information may help you make smarter investment decisions.
About SONN
More
Sonnet BioTherapeutics Holdings, Inc. is a clinical-stage, oncology-focused biotechnology company with a proprietary platform for biologic medicines of single-or bifunctional action. The Fully Human Albumin Binding (FHAB), a technology which utilizes a fully human single chain antibody fragment that binds to and hitch-hikes on human serum albumin for transport to target tissues. Its FHAB is designed to specifically target tumor and lymphatic tissue. The Company's lead program, SON-1010, or IL-12-FHAB, is in development for the treatment of solid tumors and ovarian cancer. SON-1010 is being evaluated in an ongoing Phase 1/2a study, in combination with atezolizumab (Tecentriq) for the treatment of platinum-resistant ovarian cancer (PROC). The Company is also evaluating its second program, SON-1210, an IL12-FHAB-IL15 for solid tumor. Its SON-080 program is a low dose of rhIL-6 in development for Chemotherapy-Induced Peripheral Neuropathy (CIPN) and Diabetic Peripheral Neuropathy (DPN).
Recently
Symbol
Price
%Change